Investor Presentaiton
sanofi
MenB strong phase 1/2 results demonstrate competitiveness
and support move to next phase
hSBA seroresponse rate¹
-
Sanofi MenB vs Bexsero²
Vaccine strains²
Cross-protection against strains
not in the vaccine³
MenB Formulation 1
MenB Formulation 3
hSBA seroresponse rate¹ - Sanofi MenB vs Trumenba
Vaccine strains²
MenB Formulation 1
MenB Formulation 3
Higher point estimates (>+15%)
similar (+/- 15%)
Cross-protection against strains
not in the vacine³
Lower (<15%)
> Sanofi formulations were
well tolerated
> All antigens are immunogenic
Breadth of protection
reaching expected level
1. hSBA seroresponse - % of participants with ≥ 4-fold rise of antibody titer from baseline 2. Tested strains exhibiting one of the Sanofi vaccine antigen 3. Tested strains exhibiting different antigens from the Sanofi vaccine
75 Vaccines Investor EventView entire presentation